Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Oncology Reports|July 25, 2020
lncRNA TTN‑AS1 upregulates RUNX1 to enhance glioma progression via sponging miR‑27b‑3pKeliang Chang, Genwei Wang, Jinfeng Lou, et al.
British Journal of Clinical Pharmacology|November 19, 2016
Tolerability, pharmacokinetics and antiviral activity of rHSA/IFNα2a for the treatment of chronic hepatitis B infectionYanhua Ding, Jinfeng Lou, Hong Chen, et al.
Expert Opinion on Investigational Drugs|May 16, 2022
Pharmacokinetics, safety, and tolerability of TQC3564, a novel CRTh2 receptor antagonist: report of the first-in-human single- and multiple-dose escalation trials in healthy Chinese subjectsXiaojiao Li, Qianqian Li, Tianliang Ji, et al.
The Lancet. Infectious Diseases|February 15, 2024
Safety, pharmacokinetics, and efficacy of rifasutenizol, a novel dual-targeted antibacterial agent in healthy participants and patients in China with Helicobacter pylori infection: four randomised clinical trialsXiaojiao Li, Yusi Liu, Meng Wang, et al.
Antimicrobial Agents and Chemotherapy|April 11, 2022
Safety, Tolerability, and Pharmacokinetics of the Novel Hepatitis B Virus Expression Inhibitor GST-HG131 in Healthy Chinese Subjects: a First-in-Human Single- and Multiple-Dose Escalation TrialXiaojiao Li, Yusi Liu, Hanxin Yao, et al.
The Journal of Pharmacy and Pharmacology|April 10, 2018
Clinical evaluation of efficacy, tolerability and pharmacokinetics of yimitasvir phosphate in patients infected with hepatitis C virusHong Zhang, Xiaoxue Zhu, Qingmei Li, et al.
Annals of Medicine|October 10, 2022
Safety, pharmacokinetics and pharmacodynamics of a novel γ-aminobutyric acid (GABA) receptor potentiator, HSK3486, in Chinese patients with hepatic impairmentYue Hu, Xiaojiao Li, Jingrui Liu, et al.
Frontiers in Pharmacology|June 6, 2022
First-In-Human Study on Pharmacokinetics, Safety, and Tolerability of Single and Multiple Escalating Doses of Hepenofovir, a Novel Hepatic Targeting Prodrug of Tenofovir in Healthy Chinese SubjectsHong Zhang, Lei Gao, Jinfeng Lou, et al.
Nature Communications|October 12, 2023
ZSP1601, a novel pan-phosphodiesterase inhibitor for the treatment of NAFLD, A randomized, placebo-controlled phase Ib/IIa trialYue Hu, Haijun Li, Hong Zhang, et al.
Pageof 2